key: cord-0802008-zcn4zsws
authors: Henderson, Louise M.; Benefield, Thad; Bosemani, Thangavijayan; Long, Jason M.; Rivera, M. Patricia
title: Impact of the COVID-19 pandemic on volumes and disparities in lung cancer screening
date: 2021-01-05
journal: Chest
DOI: 10.1016/j.chest.2020.12.033
sha: 8f4754552ae7ed403976f91954232ac031690198
doc_id: 802008
cord_uid: zcn4zsws

nan

The Coronavirus Disease 2019 (COVID-19) pandemic has impacted cancer screening, [1] [2] [3] with multi-state data reporting reductions in breast, colon, and cervical cancer screenings but not reporting on lung cancer screening (LCS). 4 In late April 2020, the RSNA COVID-19 Task Force suggested postponing non-urgent outpatient imaging, including lung cancer screening. 3 Also in April 2020, an expert panel of 24 physicians provided guidance for lung cancer screening (LCS) during the pandemic, stating it was appropriate to defer enrollment in LCS for new patients and delay annual screening but that patient preferences should also be considered. 1 Patients eligible for LCS have significant smoking exposure and underlying comorbidities, 5 putting this group at increased risk for infection and severe complications from COVID-19. While two studies reported reductions in LCS at the start of the pandemic, 6,7 differences in screening volumes based on patient characteristics and COVID-19 risk factors were not reported. We sought to compare LCS volumes from multiple screening centers pre and during the pandemic to determine if patients undergoing LCS differ based on sociodemographic and COVID-19 risk factors. If certain subgroups of the population are less likely to undergo LCS or delay LCS during the ongoing COVID-19 pandemic, this may impact downstream lung cancer disparities.

This analysis included all LDCT lung screening examinations occurring among adults ≥ 18 years (98.7% aged 55-80 years) at two academic and two community imaging sites affiliated with the University of North Carolina Healthcare System from 01/01/2019 to 09/30/2020. Patient characteristics included age, sex, race, smoking status, body mass index (BMI), J o u r n a l P r e -p r o o f hypertension, chronic obstructive pulmonary disease (COPD), and patient residence. We classified screening exams as initial LDCT versus returning for annual screening exams as part of routine care. This study was approved by the Institutional Review Board of the University of North Carolina at Chapel Hill.

We conducted two analyses. First, to compare LCS volumes pre-and during the pandemic, we utilized an interrupted time series analysis assigning the date of the first COVID-19 diagnosis in NC as the intervention date (03/03/2020). We calculated the predicted mean number of examinations per month in the pre-COVID time period (01/01/2019 to 03/02/2020) and each subsequent month. For each time period (pre-COVID and subsequent months), this involved computing two predicted mean: one accounting for COVID and one assuming an absence of COVID. We then calculated differences between these two predicted means for each post-COVID month, along with 95% confidence intervals (CIs). Finally, for the first analysis, we calculated the percentage difference in the predicted monthly means given the onset of the COVID-19 pandemic, compared to predicted monthly means in the absence of the COVID-19 pandemic. The overall effect of COVID on screening volume was tested using the likelihood ratio test.

In our second analysis, we investigated whether changes in receipt of LCS "Stay-At-Home Order" was lifted, but other restrictions remained and the healthcare system began scheduling initial and follow up LCS exams. Random-effects models were used to generate predicted probabilities of outcomes by time period. Pairwise differences in predicted probabilities by time period were computed, with p-values adjusted using the false discovery rate to control for Type 1 error. 8 All statistical analysis was conducted using SAS v9.4 (SAS Institute, Cary, NC). Two-sided P-values less than 0.05 were considered statistically significant. Comparison of patient characteristics during the pre-COVID time period to each of the three time periods during the pandemic found no significant differences for age, sex, race, smoking status, BMI, COPD, hypertension, or patient residence (p>0.05 for all; Table 1 ). The proportion of initial LDCT LCS exams was highest in the pre-COVID time period (53.8%) and J o u r n a l P r e -p r o o f decreased in all three subsequent time periods: 50.7% during Beginning of Pandemic, 49.7% during Shut Down, and 48.6% during Ramp-Up, with significant differences between the pre-COVID and Ramp-Up time periods (p=0.0072).

Despite sharp reductions in LCS volumes at the start of the pandemic, LCS volumes returned to pre-COVID-19 levels by June 2020 and remained at pre-COVID volumes through September 2020. Our results are in line with the 62% reduction in LCS volume reported by the PROSPR consortium 7 and with the 74% reported by Lang et al. 6 We found that the proportion of initial LCS examinations decreased from 53.8% in the pre-COVID time period to 48.6% in the Ramp-Up time period, with almost half of LCS occurring in new patients during the pandemic.

This finding is counter to the CHEST expert panel's suggestion that new patients forgo enrollment in LCS during the pandemic and may reflect local transmission rates or the availability of resources. 1 Our results may be explained by differences in how the CHEST consensus statement regarding LCS during the pandemic was communicated within sites and to providers who refer patients for LCS. This is an area that warrants further investigation to understand best strategies for rapid dissemination of recommendations across screening programs.

Our results do not demonstrate differences in LCS volumes pre-versus during COVID among non-white patients or rural patients, both of which have persistently experienced disparities in lung cancer outcomes and other cancer screening modalities. 9 Additionally, our results do not suggest that patients at high-risk of COVID complications (i.e. patients who are J o u r n a l P r e -p r o o f obese, have COPD or hypertension) were less likely to undergo LCS. Our study is limited to four lung imaging sites in one state and our findings should be confirmed in other geographic areas where pandemic responses may have differed. As the pandemic continues to surge, ongoing monitoring of cancer screening and downstream consequences on cancer diagnoses are needed to ensure all patients receive the highest quality care.

J o u r n a l P r e -p r o o f

Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic

Cancer Screening During the COVID-19 Pandemic

COVID-19 Task Force. RSNA COVID-19 Task Force: Best Practices for Radiology Departments during COVID-19

Preventive cancer screenings during COVID-19 pandemic

Comorbidities, Smoking Status, and Life Expectancy Among Individuals Eligible for Lung Cancer Screening

Operational challenges of a low-dose CT lung cancer screening program during the COVID-19 pandemic

Cancer Screening during COVID-19: A Perspective from NCI's PROSPR consortium

Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing

Addressing Disparities in Lung Cancer Screening Eligibility and Healthcare Access

J o u r n a l P r e -p r o o f